Myriad Genetics (MYGN) Gross Profit (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Gross Profit data on file, last reported at $137.6 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $137.6 million, up 2.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $580.0 million (changed 0.34% YoY), and the FY2025 annual result was $576.6 million, down 1.5% from the prior year.
• Gross Profit declined to $137.6 million in Q1 2026 per MYGN's latest filing, from $146.8 million in the prior quarter.
• Over five years, Gross Profit peaked at $151.8 million in Q2 2025 and troughed at $59.1 million in Q4 2022.
• A 5-year average of $128.0 million and a median of $134.3 million in 2023 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2024: Gross Profit plunged 79.54% in 2022, then soared 84.02% in 2024.
• A 5-year view of Gross Profit shows it stood at $59.1 million in 2022, then soared by 38.75% to $82.0 million in 2023, then surged by 84.02% to $150.9 million in 2024, then decreased by 2.72% to $146.8 million in 2025, then fell by 6.27% to $137.6 million in 2026.
• Business Quant data shows MYGN's Gross Profit at $137.6 million in Q1 2026, $146.8 million in Q4 2025, and $143.8 million in Q3 2025.